Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michelle Jäschke"'
Autor:
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susane Krege, Jürgen Gschwend, Heidrun Rexer, Michael Stöckle
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-9 (2017)
Abstract Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is t
Externí odkaz:
https://doaj.org/article/690cf09f4623408381878b95f241dadc
Autor:
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susanne Krege, Jürgen Gschwend, Heidrun Rexer, Kerstin Junker, Roger Zillmann, Christoph Rüssel, Eva Hellmis, Henrik Suttmann, Martin Janssen, Jan Marin, Andreas Hübner, Michael Mathers, Jochen Gleißner, Michael Scheffler, Susan Feyerabend, Jens Telle, Jörg Klier, Michael Stöckle
Background Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abirateron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8e19dd991763bf7d9060ca36a498e3b
Autor:
Michelle Jäschke, Katharina Kramer, Lucia E. Groß, Ken Fischer, Christian Ehmann, Uwe Bodensohn, Roman Ladig, Stefan A. Rensing, Enrico Schleiff, Stefan Simm
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1866:1650-1662
The guided entry of tail-anchored proteins (GET) pathway facilitates targeting and insertion of tail-anchored proteins into membranes. In plants, such a protein insertion machinery for the endoplasmic reticulum as well as constituents within mitochon
Autor:
Jürgen E. Gschwend, Michelle Jäschke, Peter Jaehnig, Carsten-Henning Ohlmann, Heidrun Rexer, Michael Stöckle, Susane Krege
Publikováno v:
Trials
Trials, Vol 18, Iss 1, Pp 1-9 (2017)
Trials, Vol 18, Iss 1, Pp 1-9 (2017)
Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is the prolon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d742b887e3018b3109a943d8cf2464db
https://www.ncbi.nlm.nih.gov/pubmed/28978327
https://www.ncbi.nlm.nih.gov/pubmed/28978327